Tagged with Cell & Gene

USA Paediatric oncologist Navin Pinto, MD outlines the current use and potential of CAR-T therapies in his field, including the manufacturing challenges that still need to be addressed. Dr Pinto also explains how the work of his CAR-T team at the University of Washington School of Medicine could provide proof of…

Global PharmaBoardroom has spoken to leaders from several important global patient advocacy organisations in 2021 who shared their concerns on crucial global healthcare issues. These range from the greater levels of pharma industry investment needed in childhood cancers; the myriad of patient explanation and expectation management needed around CAR-T therapies; how…

USA Claire Saxton and Lauren Kriegel of Cancer Support Community, the largest professionally led non-profit network of cancer support worldwide, discuss how cancer patient and caregiver perspectives need to be better integrated into the treatment process. This is an especially prescient issue for next-generation cell and gene therapies such as CAR-T…

Denmark Danish pharma industry veteran Peter Drøidal highlights how he steered the Danish Novartis affiliate through the COVID-19 pandemic period, the strategy in place to navigate an increasingly challenging market access landscape, and the lessons that can be leveraged from the value-based agreement that Novartis was able to strike with the…

Global Lorna Warwick is CEO of the Lymphoma Coalition, a worldwide network of patient groups with a full or partial focus on providing support to patients with lymphoma. In this wide-ranging interview, Warwick highlights the progress made in lymphoma treatment in recent years and the work still to be done to…

Switzerland Swiss-based Lonza has consolidated as a titan in the CDMO industry with annual revenues of around CHF 5.9bn for 2020. Its president for the Biologics and Cell & Gene divisions, Jean-Christophe Hyvert, comments on the restructuring of the company, why the divesture of the specialty ingredients division makes sense in…

USA Dr Sam Volchenboum outlines the progress that has been made in the paediatric oncology field in recent years and his hopes for its future. Dr Volchenboum also explains the important role that data will play in the new era of targeted and personalised therapies and the impact of the work…

Global Cancer is one of the most frightening words in any language but is especially heart-wrenching when it comes to children. João de Bragança, President of Childhood Cancer International (CCI) and Nicole Scobie, President of Zoé4life and CCI European Board Member, share CCI’s aims as the largest parent-led international organisation supporting…

China A historic approval for Fosun-Kite’s CAR-T therapy Yescarta in China looks set to pave the way for further developments in the Chinese cell and gene therapy space, as multinationals look to bring their new therapies to the rapidly expanding China market   Yescarta, originally approved in the US in 2017…

Switzerland The Novartis and Roche names are synonymous with Swiss pharmaceutical innovation. But for these two Basel-based global behemoths, what value does Switzerland itself hold and what do they see as the areas in which they can truly bring value in their home market?   Roche – Driving Digital & Personalised…

Asia-Pacific Asia-Pacific, as home to 50 percent of the world’s new cancer cases each year and with deaths caused by cancer expected to increase by 36 percent by 2030, has a pressing need for more patient-centric, data-driven, value-based, and precise solutions in oncology. Additionally, Asian cancer patients’ healthcare needs can differ…

Singapore Lucas Chan, Scientific Founder and CSO of CellVec, a Singapore-based CDMO that specializes in the development and manufacture of viral vectors for clinical gene therapy, discusses how his company is helping companies with mature preclinical gene therapy projects wanting to progress into the clinic. Moreover, he discusses why Singapore is…